Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 25;39(2):110680. doi: 10.1016/j.celrep.2022.110680

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Antibody response of an octogenarian population elicited by two vaccine doses 15 and 20 months after SARS-CoV-2 infection

(A) Sixteen nuns (median age 81 years old) received one dose of the BNT162b2 vaccine 15 months after recovering from COVID-19 and a second dose after another 5 months. Blood was collected over a period of 20 months as indicated by the colored circles.

(B) Co-morbidities. The co-morbidities of each individual are listed in Table S1.

(C–G) Plasma IgG antibody binding the SARS-CoV-2 RBD (spike) from different variants and the N protein within 15 months after infection (C and D), after the first dose vaccination (E and F), and after the second vaccination (G). p values are from two-way ANOVA with Tukey’s multiple comparisons test (C, E, and G) and unpaired t test with Welch’s correction (D and F). ^∗p < 0.05, ^∗∗p < 0.01, ^∗∗∗p < 0.001, and ^∗∗∗∗p < 0.0001 (2 mo, n = 16; 10 mo, n = 5; 15 mo [D0], n = 16; 15 mo [D7], n = 15; 17.5 mo, n = 16; 19 mo, n = 8; 20 mo [D0], n = 7; 20 mo [D7], n = 7).

(H) Neutralizing antibody response to Delta (B.1.617.2). p values are from one-way ANOVA with Tukey’s multiple comparisons test. ^∗∗p < 0.01. The individual data are listed in Table S2. Colors in dot plots were matched to the ones in timeline in (A) (15 mo [D0], n = 16; 15 mo [D7], n = 15; 17.5 mo, n = 16).

(I) Blocking of interactions between ACE2 and SARS-CoV-2 spike (RBD) interactions was tested by competition ELISA. p values are from two-way ANOVA with Sidak’s multiple comparisons test. ^∗p < 0.05 and ^∗∗∗p < 0.001 (15 mo [D7], n = 7; 20 mo [D7], n = 7).